EGFR and non-small cell lung carcinoma: For example, when osimertinib is treated as a second‐line treatment in addition to first‐line treatment with first‐ or second‐generation EGFR‐TKIs, survival after progression has a stronger effect on the OS of patients with secondary T790M mutation‐positive NSCLC; however, PPS may also be of value when osimertinib is used as a first‐line treatment beyond postoperative recurrence.